Furthermore, the lack of expression differences between Tmem27 on islets from healthy versus T2D subjects [56] and the loss of beta-cells during T2D disease progression poses the question of relevance of BACE2-mediated inhibition of TMEM27 cleavage as a therapy in humans. The gene discussed is BACE2; the disease is type 2 diabetes mellitus.